JPWO2022031695A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022031695A5
JPWO2022031695A5 JP2023507633A JP2023507633A JPWO2022031695A5 JP WO2022031695 A5 JPWO2022031695 A5 JP WO2022031695A5 JP 2023507633 A JP2023507633 A JP 2023507633A JP 2023507633 A JP2023507633 A JP 2023507633A JP WO2022031695 A5 JPWO2022031695 A5 JP WO2022031695A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536630A5 (https=
JP2023536630A (ja
JP7854423B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044330 external-priority patent/WO2022031695A1/en
Publication of JP2023536630A publication Critical patent/JP2023536630A/ja
Publication of JP2023536630A5 publication Critical patent/JP2023536630A5/ja
Publication of JPWO2022031695A5 publication Critical patent/JPWO2022031695A5/ja
Application granted granted Critical
Publication of JP7854423B2 publication Critical patent/JP7854423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507633A 2020-08-04 2021-08-03 Ｐｄ－ｌ１結合性作用剤およびその使用 Active JP7854423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061109P 2020-08-04 2020-08-04
US63/061,109 2020-08-04
PCT/US2021/044330 WO2022031695A1 (en) 2020-08-04 2021-08-03 Pd-l1 binding agents and uses thereof

Publications (4)

Publication Number Publication Date
JP2023536630A JP2023536630A (ja) 2023-08-28
JP2023536630A5 JP2023536630A5 (https=) 2024-08-08
JPWO2022031695A5 true JPWO2022031695A5 (https=) 2024-08-08
JP7854423B2 JP7854423B2 (ja) 2026-05-01

Family

ID=

Similar Documents

Publication Publication Date Title
JP2024150445A5 (https=)
JP2021533726A5 (https=)
JP2018531219A (ja) Ｐｄ−ｌ１抗体
JP2018531219A6 (ja) Ｐｄ−ｌ１抗体
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
AU2016233495A2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP2026041845A5 (https=)
JP2024016024A5 (https=)
JP2017507131A5 (https=)
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用
JP2025507938A (ja) 抗ｐｄ－ｌ２抗体
CA3255552A1 (en) TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY
JP2018531625A5 (https=)
JPWO2020191342A5 (https=)
WO2002072008A9 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
JPWO2022031710A5 (https=)
WO2023222135A1 (en) A method of treating solid tumor
JPWO2020206033A5 (https=)
JPWO2023154730A5 (https=)
JPWO2023028653A5 (https=)
JP7641292B2 (ja) 抗ｃｄ１９抗体、その使用方法及び製造方法
JPWO2022031695A5 (https=)
JPWO2019228514A5 (https=)
JPWO2021042019A5 (https=)